Nice | Idelalisib for treating chronic lymphocytic leukaemia

15th February 2016 by Louise Hudman

Nice | Idelalisib for treating chronic lymphocytic leukaemia

This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.

Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a ‘first-in-class’ drug which inhibits enzymes involved in cell proliferation, death and migration.

Side-effects

Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"The NASGP and the GP locum chambers that I'm in have provided invaluable assistance both before and through Covid-19 to me as a full-time GP locum. All aspects of locum work have been made easier as a result of membership and the chamber's support structure - from accessing work, to ensuring invoicing and documentation is all sorted, and access to other locums as peer support. Having a chamber manager means I feel more secure and can devote more of my energy on my clinical work."

Dr Richard Smith

Dr Richard Smith

See the full list of features within our NASGP membership plans

Membership